BDM PHARMA
ActiveSummary
The computed 12-month bankruptcy probability of BDM PHARMA is 4.4% (elevated). The 2025 annual accounts show negative equity (€-20k) and a net result of €-12k. Equity is shrinking by ~135.5% per year across the filed fiscal years. Its solvency ranks better than 11% of 4157 sector peers (fiscal year 2025). The company has been active since 2022 and the Belgian State Gazette contains no insolvency or warning signals.
Checked score
Score 2025
25
/ 100
Weak
The score weighs solvency, liquidity, profitability and financial development. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability20▲+2
Solvency22▼-2
Growth32=
Track record94
Bankruptcy probability, 12 months
4.4%
Elevated
0%0.5%1.5%4%10%≥ 25%
No credit on open account
Liquidity short (current ratio 0.09 against 0.13 in 2024; short-term debt: 53.7% and cash: 0.2% of total assets), and equity is negative.
Credit advice for your own amount and term
Signals
Six signals. The signal on the left, the evidence on the right.
+raises risk○neutral
raises risk · Limited track record
This company has not been active as long as an established one and statistically fails somewhat more often.
KBO · incorporation dateAge against the risk zone
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Sector 47
higher
← fewer bankruptcies
more bankruptcies →
raises risk · Annual accounts: weaker financial profile
The latest annual accounts show a weaker profile in solvency, result or liquidity than companies that stay afloat.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
-2.5%
Return on assets
-1.6%
Age of the figures
12 mo
raises risk · Negative equity
The 2025 annual accounts show negative equity and a net loss.
NBB · annual accounts 2025Equity per financial year
232425
2023 to 2025 · latest year €-20k
neutral · Latest accounts filed on time
The financial year that closed on 30-09-2025 was due by 30-04-2026 and was filed on 13-04-2026, 17 days ahead of the deadline.
NBB · 3 filingsDeviation from the deadline
2025
17 d early
2024
on the day
2023
22 d late
← before the deadline
after the deadline →
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 30-09-2026 and is due by 30-04-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
24-09-2026 today30-09-2026 close30-04-2027 deadline
Financials · fiscal year 2025, full schema
Turnover
Not included in this filing
EBIT margin
Not included in this filing
Net result
€-12k▲ 35.5%
2024 · €-19k
2023: €10k
2024: €-19k
2023 → 2025
Working capital
€-381k▼ 6.9%
2024 · €-356k
2023: €12k
2024: €-356k
2023 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line202320242025Trend
Equity€12k-€-8k€-20k▼ 164%
Operating result€11k-€5k▼ 58.3%€8k▲ 75.1%
Net result€10k-€-19k€-12k▲ 35.5%
Result per fiscal year
Operating resultNet result
The operating result recovers in 2025; 2025 is 75% above 2024.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €783k
Fixed assets
€743k ▼ 0.1%
Current assets
€40k ▼ 25.1%
Key figures and ratios
EBITDA
€9k▲
2024 · €5k
Cash flow
€-12k▲
2024 · €-19k
Solvency
-2.5%▼
2024 · -0.9%
Current ratio
0.09▼
2024 · 0.13
Debt to equity
-40.36
ROA
-1.6%▲
2024 · -2.4%
Interest coverage
0.43▲
2024 · 0.29
Debt
€803k▼
2024 · €804k
Debt ≤ 1 year
€421k▲
2024 · €409k
Debt > 1 year
€382k▼
2024 · €395k
Income taxes
€391▼
2024 · €6k
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Filed annual accounts As filed with the NBB · 2025 against 2024 · 45 lines
Balance sheet
Code20242025
Assets
Total assets20/58€796k€783k▼
Fixed assets21/28€743k€743k▼
Tangible fixed assets22/27€485€71▼
Furniture and vehicles24€485€71▼
Financial fixed assets28€743k€743k=
Current assets29/58€53k€40k▼
Amounts receivable within one year40/41€51k€38k▼
Trade receivables40€18k€34k▲
Other amounts receivable41€33k€4k▼
Cash at bank and in hand54/58€2k€1k▼
Deferred charges and accrued income490/1-€366
Equity and liabilities
Total equity and liabilities10/49€796k€783k▼
Equity10/15€-8k€-20k▼
Contributions10/11€2k€2k=
Outside capital11€2k-
Other1109/19€2k-
Reserves13€200€200=
Distributable reserves133€200€200=
Profit (loss) carried forward14€-10k€-22k▼
Amounts payable17/49€804k€803k▼
Amounts payable after more than one year17€395k€382k▼
Financial debts170/4€375k€362k▼
Other amounts payable178/9€20k€20k=
Amounts payable within one year42/48€409k€421k▲
Current portion of amounts payable after more than one year42€353k€35k▼
Trade debts44€930€4k▲
Suppliers440/4€930€4k▲
Taxes, remuneration and social security45€13k€6k▼
Taxes450/3€13k€6k▼
Other amounts payable47/48€42k€375k▲
Income statement
Code20242025
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€414€414=
Other operating charges640/8€63€63=
Gross operating margin9900€5k€9k▲
Operating profit (loss)9901€5k€8k▲
Financial income75/76B€13€25▲
Recurring financial income75€13€25▲
Financial charges65/66B€18k€20k▲
Recurring financial charges65€18k€20k▲
Profit (loss) for the period before taxes9903€-13k€-12k▲
Income taxes67/77€6k€391▼
Profit (loss) for the period9904€-19k€-12k▲
Profit (loss) for the period to be appropriated9905€-19k€-12k▲
Appropriation of the result
Profit (loss) to be appropriated9906€-10k€-22k▼
Profit (loss) brought forward from the previous period14P€9k€-10k▼
Social balance
Average headcount (FTE)9087-0.0
The notes to these accounts (11 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
13-04
NBB filing
Annual accounts filed
fiscal year 2025 · full schema
2025
30-04
NBB filing
Annual accounts filed
fiscal year 2024 · full schema
2024
30-09
Financial
Weakest financial yearnet €-19k ▼299%
Net result drops to €-19k, the lowest in the series; recovery starts the following year.
22-05
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema · 22 days late
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
1 act for this company is in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Sint-Lambrechts-Woluwe · 1 establishment unit since 2022
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Paul Hymanslaan 1121200 Sint-Lambrechts-WoluweGround area
1,828 m²
Building footprint
311 m²
Volume, LiDAR
11,610 m³
Parcel 21672C0058/00M006, Brussels · tallest building 40.4 m, ±12 floors. Linked by address, not a title deed.
1 establishment unit
BDM PHARMA
since 20222.329.247.439
1 parcel
Brussels
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 21672C0058/00M006 | Brussels | 1,828 m² | 1 · 311 m² | 40.4 m · 12 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
APOTHEEK VAN CAUSBROECK
BE 0472.757.610
Dendermonde · Eq €11,578
PHARMACIE DES PAGODES
BE 0875.872.386
Genappe · Eq €11,549
LN PHARMA CONSULTING
BE 0751.561.740
Seraing · Eq €11,501
PH DE LINDE
BE 0789.794.091
Anderlecht · Eq €11,781
PHARMAELA
BE 0802.941.155
Quaregnon · Eq €11,788
Of 5,220 companies in sector 47730 we hold annual accounts for 3,861. 933 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded10-03-2022
Fiscal year end30-09
Activities, NACEBEL 2025
47730Retail sale of pharmaceutical products
Sources
Crossroads Bank for EnterprisesNational Bank · 3 filingsAddress and cadastre registers
Scores and ratios are computed by Checked and are not a credit decision.